Barclays PLC Grows Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Barclays PLC boosted its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 91.1% during the third quarter, Holdings Channel reports. The firm owned 84,572 shares of the company’s stock after purchasing an additional 40,319 shares during the quarter. Barclays PLC’s holdings in Amylyx Pharmaceuticals were worth $274,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMLX. FMR LLC boosted its stake in shares of Amylyx Pharmaceuticals by 292.0% in the 3rd quarter. FMR LLC now owns 221,001 shares of the company’s stock worth $716,000 after buying an additional 164,622 shares during the last quarter. abrdn plc lifted its holdings in Amylyx Pharmaceuticals by 1,567.9% in the third quarter. abrdn plc now owns 1,972,242 shares of the company’s stock valued at $6,390,000 after acquiring an additional 1,853,995 shares during the period. Alpha Wave Global LP purchased a new position in Amylyx Pharmaceuticals in the third quarter worth about $2,169,000. Almitas Capital LLC bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at about $3,617,000. Finally, AQR Capital Management LLC lifted its stake in shares of Amylyx Pharmaceuticals by 2,768.0% in the 2nd quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company’s stock worth $6,348,000 after purchasing an additional 3,224,454 shares during the period. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Analyst Ratings Changes

AMLX has been the subject of several recent research reports. Baird R W upgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Bank of America upgraded Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the company from $4.20 to $10.00 in a research report on Wednesday, October 23rd. Leerink Partners set a $4.00 price target on Amylyx Pharmaceuticals and gave the company a “market perform” rating in a report on Friday, October 18th. Finally, Robert W. Baird raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. Five investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX stock opened at $3.60 on Tuesday. The stock has a fifty day simple moving average of $4.54 and a two-hundred day simple moving average of $3.53. The firm has a market capitalization of $246.78 million, a PE ratio of -0.94 and a beta of -0.53. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $19.95.

Insider Transactions at Amylyx Pharmaceuticals

In related news, CEO Justin B. Klee sold 7,471 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $4.04, for a total transaction of $30,182.84. Following the sale, the chief executive officer now owns 3,176,788 shares of the company’s stock, valued at approximately $12,834,223.52. This trade represents a 0.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 11.70% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.